PMID- 35412172
OWN - NLM
STAT- MEDLINE
DCOM- 20220719
LR  - 20220818
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 40
IP  - 4
DP  - 2022 Aug
TI  - The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in 
      patients with advanced non-small-cell lung cancer: a meta-analysis.
PG  - 810-817
LID - 10.1007/s10637-022-01232-8 [doi]
AB  - OBJECTIVE: To evaluate the efficacy and safety of immune checkpoint inhibitor 
      (ICI) and chemotherapy (CT) versus CT alone in advanced non-small-cell lung 
      cancer (NSCLC). METHODS: Databases (PubMed, Embase and Cochrane Library) were 
      searched for relevant randomized controlled trials (RCTs). Clinical outcome 
      measures including overall survival (OS), progression-free survival (PFS), 
      objective response rate (ORR), and grade 3-5 treatment-related adverse events 
      (AEs) were analyzed by Stata 15.0 software; significance level was 0.05. RESULTS: 
      Eight RCTs involving 4227 patients were included. The results showed ICI + CT 
      significantly improved OS (hazard ratio [HR] = 0.74, 95% CI: 0.62-0.85, 
      p < 0.001), PFS (HR = 0.66, 95% CI: 0.57 - 0.75, p < 0.001) and ORR (odds ratio 
      [OR] = 1.89; 95% CI, 1.43-2.49, p < 0.001) compared with CT alone. Subgroup 
      analysis indicated that significantly longer OS was also observed in subgroups 
      including combination regimens (pembrolizumab + CT, atezolizumab + CT, 
      ipilimumab + CT, and nivolumab + ipilimumab + CT) and PD-L1 status [negative 
      (< 1%), positive (>/= 1%), low (1-49%) and high (>/= 50%)]. However, ICI + CT showed 
      signifcantly higher grade 3-5 treatment-related AEs than CT (OR = 1.46, 95% CI: 
      1.19 - 1.79, p < 0.001). CONCLUSIONS: ICI + CT showed better clinical efficacy 
      than CT alone in patients with advanced NSCLC, with increased treatment-related 
      AEs.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Meng, Li-Fang
AU  - Meng LF
AUID- ORCID: 0000-0003-0606-3048
AD  - Respiratory Department, Binyang County People's Hospital, Ren-Ai Street No.137, 
      Binyang, Guangxi, China. xinfang121627@163.com.
FAU - Huang, Jian-Feng
AU  - Huang JF
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, 530000, Nanning, Guangxi, China.
FAU - Luo, Peng-Hui
AU  - Luo PH
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, 530000, Nanning, Guangxi, China.
FAU - Huang, Shang-Xiao
AU  - Huang SX
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, 530000, Nanning, Guangxi, China.
FAU - Wang, Han-Lei
AU  - Wang HL
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, 530000, Nanning, Guangxi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20220412
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Ipilimumab)
SB  - IM
MH  - *Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology
MH  - Humans
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - Ipilimumab/therapeutic use
MH  - *Lung Neoplasms/drug therapy/pathology
OTO - NOTNLM
OT  - Efficacy and safety
OT  - Immune checkpoint inhibitor
OT  - Non-small-cell lung cancer
OT  - PD-1/PD-L1
OT  - PD-L1 expression level
EDAT- 2022/04/13 06:00
MHDA- 2022/07/20 06:00
CRDT- 2022/04/12 12:07
PHST- 2022/01/12 00:00 [received]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
PHST- 2022/04/12 12:07 [entrez]
AID - 10.1007/s10637-022-01232-8 [pii]
AID - 10.1007/s10637-022-01232-8 [doi]
PST - ppublish
SO  - Invest New Drugs. 2022 Aug;40(4):810-817. doi: 10.1007/s10637-022-01232-8. Epub 
      2022 Apr 12.